Merck & Company Inc (MRK) — closed signal from April 17, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on July 16, 2026.
Predicted vs. what happened
MRK price · publication thesis → realized outcomesplit-adjusted
$112.38 – $116.32Entry zone — fair-value band
$116.08Published — price the day we called it
$127.92Target — the price the thesis aimed for
$130.29Peak — highest point inside the window, not a realized return
$127.63Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 73 days.
Peak price
$130.29
peak on June 30, 2026 — not a realized returnPeak gain
+12.2%
peak, from the publication priceWindow close
$127.63
end-of-window price, context onlyDays to target
73
Window
April 17, 2026 – July 16, 2026
The thesis — published April 17, 2026
Predicted growth
+11%
over the measurement windowTarget price
$127.92
the price the thesis aimed forEntry zone
$112.38 – $116.32
the fair-value band we waited forPrice at publication
$116.08
published April 17, 2026Confidence
75%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Merck looks like a steadier healthcare pick because its near-term story depends on real drug news, not market hype. EU approval for clesrovimab and a priority review for ifinatamab boost visibility for upcoming products. Shares appear sold-off, and solid profits and valuation give some protection. If sentiment improves, a 0-3 month rebound is plausible.
Primary drivers
- New approval and priority review increase near-term product visibility
- Good valuation and profitability reduce downside risk
- Adds healthcare balance to a tech-heavy mix
- Recent selling leaves room to recover if price steadies
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.